Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 6/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888869 | 0.84 | KDM4E (0.54) | NPC1 | |
| SCHEMBL11888886 | 0.83 | CYP2C9 (0.56) | SCDPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11888910 | 0.81 | CNR1 (0.47) | NPC1CYP46A1 | |
| SCHEMBL937498 | 0.79 | GPR183 (0.50) | GPR183HCRTR1HCRTR2SCDSMO | |
| SCHEMBL30691929 | 0.79 | GPR183 (0.50) | GPR183HCRTR1HCRTR2SCDSMO | |
| SCHEMBL1147339 | 0.79 | EPHX2 (0.44) | GPR183HCRTR1HCRTR2SCDSMO | |
| SCHEMBL11889045 | 0.75 | HSD11B1 (0.53) | GPR183 | |
| SCHEMBL5935437 | 0.73 | GPR119 (0.49) | HCRTR1HCRTR2SCDSMOP2RX7 | |
| SCHEMBL11888882 | 0.72 | HTT (0.60) | — | |
| SCHEMBL17938731 | 0.72 | GPR183 (0.51) | GPR183HCRTR1HCRTR2SCDSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480532-B1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | claimed |
| EP-2480532-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| CN-102471265-A | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | claimed |
| EP-2480532-B1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2480532-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| CN-102471265-A | Piperidine derivatives and their use for the treatment of obesity, diabetes, dyslipidemia and atherosclerosis | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |